In the trials, omalizumab and multi-allergen oral immunotherapy showed alike efficacy in protecting against food allergies, ...

An Indian origin scientist Vinod Balachandran, MD, in latest data from the phase 1 trial has revealed that an investigational ...

Scientists have developed a new chemical method that could make it easier, safer and more environmentally friendly to create ...

Bernstein analyst Justin Smith maintained a Buy rating on Roche Holding AG (RHHVF – Research Report) today and set a price target of CHF345.00.

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Roche Holding AG (RHHVF – Research Report) ...

TAGRISSO has become a standard treatment due to its strong efficacy in both first-line and adjuvant settings. The growing prevalence of EGFR mutations, a rise in lung cancer diagnoses, and broader ...

BREYANZI has significant market potential due to its innovative approach as a CD19-directed chimeric antigen receptor (CAR) T-cell therapy. The growing prevalence of hematologic malignancies ...

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world ...

Indian-origin doctor Dr. Vinod Balachandran leads groundbreaking research at Memorial Sloan Kettering Cancer Center, ...